keyword
MENU ▼
Read by QxMD icon Read
search

Deauville lymphoma

keyword
https://www.readbyqxmd.com/read/28696028/pretransplant-functional-imaging-and-outcome-in-pediatric-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-transplantation
#1
Nmazuo W Ozuah, Hisham M Dahmoush, Frederick D Grant, Leslie E Lehmann, Ann S LaCasce, Amy L Billett, Steven P Margossian
BACKGROUND: Pretransplant functional imaging (FI), particularly a negative positron emission tomography (PET), is a strong predictor of outcome in adults with relapsed or refractory Hodgkin lymphoma (HL), but data in pediatrics are limited. METHODS: The medical records of 49 consecutive pediatric patients, who received autologous transplant at a single institution, were retrospectively analyzed. All patients had either gallium or PET scan before transplant and were conditioned with carmustine, etoposide, cytarabine, and melphalan (BEAM)...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28692029/pre-autologous-transplantation-pet-ct-using-deauville-criteria-is-an-independent-predictor-of-progression-in-relapsed-refractory-classical-hodgkin-lymphoma
#2
M Damlaj, S Ghazi, G Syed, T Pasha, G Gmati, H Salama, O Ali, K A Abuelgasim, M Al-Zahrani, A Hejazi, A Al Askar
No abstract text is available yet for this article.
July 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28686510/somatostatin-receptor-expression-in-lymphomas-a-source-of-false-diagnosis-of-neuroendocrine-tumor-at-68-ga-dotanoc-pet-ct-imaging
#3
Tiina Ruuska, Yadith Ramírez Escalante, Samuli Vaittinen, Maria Gardberg, Aida Kiviniemi, Päivi Marjamäki, Jukka Kemppainen, Sirkku Jyrkkiö, Heikki Minn
BACKGROUND: (68)Ga-DOTANOC PET/CT is routinely used to image neuroendocrine tumors (NETs). A case of lymphoma initially thought to be NET based on a positive (68)Ga-DOTANOC PET/CT was recently seen at our institution. This prompted us to determine prospectively somatostatin receptor (SSTR) status in patients with lymphoma by immunohistochemical analysis of SSTR subtypes 2, 3 and 5 (SSTR2,3,5) and (68)Ga-DOTANOC PET/CT imaging. MATERIAL AND METHODS: Twenty-one patients with newly diagnosed lymphoma were referred to (68)Ga-DOTANOC and FDG PET/CT prior to any treatment...
July 7, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28660348/the-role-of-f-18-fdg-pet-ct-in-evaluating-the-impact-of-hiv-infection-on-tumor-burden-and-therapy-outcome-in-patients-with-hodgkin-lymphoma
#4
Ismaheel O Lawal, Nozipho E Nyakale, Lerwine M Harry, Moshe R Modiselle, Alfred O Ankrah, Alphonse P Msomi, Neo P Mokgoro, Tebatso G Boshomane, Christophe Van de Wiele, Mike M Sathekge
BACKGROUND: To evaluate the impact of HIV infection on tumor burden and therapy outcome following treatment with chemotherapy in patients with Hodgkin lymphoma. METHODS: A total of 136 patients with classical Hodgkin lymphoma were studied (mean age ± SD = 32.31 ± 1.39 years, male = 86, female = 50). Advanced disease (stage III and IV) was present in 64% of patients. HIV infection was present in 57 patients while 79 patients were HIV-negative. Baseline F-18 FDG PET/CT was obtained in all patients...
June 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28634685/poor-predictive-value-of-positive-interim-fdg-pet-ct-in-primary-mediastinal-large-b-cell-lymphoma
#5
Julien Lazarovici, Marie Terroir, Julia Arfi-Rouche, Jean-Marie Michot, Sacha Mussot, Valentina Florea, Maria-Rosa Ghigna, Peggy Dartigues, Cynthia Petrovanu, Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients)...
June 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28629257/risk-stratification-of-diffuse-large-b-cell-lymphoma-with-interim-pet-ct-based-on-different-cutoff-deauville-scores
#6
Jihyun Kim, Yoo Sung Song, Jong Seok Lee, Won Woo Lee, Sang Eun Kim
We evaluated the usefulness of interim (18)F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). One hundred and fifty patients underwent interim (I-) and end of treatment (EOT-) PET/CT scans. Applying the conventional 5-DS cutoff value of scores 4 to 5 at interim, there was no significant difference in progression free survival (PFS) between I-PET negative and I-PET positive patients...
June 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535082/evaluating-early-interim-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-with-the-suvmax-liver-based-interpretation-for-predicting-the-outcome-in-diffuse-large-b-cell-lymphoma
#7
Yang Fan, Yuewei Zhang, Zhi Yang, Zhitao Ying, Nina Zhou, Chen Liu, Yuqin Song, Jun Zhu, Xuejuan Wang
Interim (18)F-FDG PET/CT is an effective predictor in patients with DLBCL, but the standard evaluating criteria were controversial. In this study, investigators tried to investigate whether the liver SUVmax (SUVmax-liver)-based interpretation could improve the accuracy of predicting the outcomes, comparing with the Deauville five-point scale (5-PS) and the reduction rate of the maximum standardized uptake value (ΔSUVmax) criteria. In 119 patients, PET/CT after two chemotherapy cycles (PET2) were evaluated with the SUVmax-liver-based interpretation, 5-PS, and ΔSUVmax criteria...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28513853/association-between-textural-and-morphological-tumor-indices-on-baseline-pet-ct-and-early-metabolic-response-on-interim-pet-ct-in-bulky-malignant-lymphomas
#8
Fayçal Ben Bouallègue, Yassine Al Tabaa, Marilyne Kafrouni, Guillaume Cartron, Fabien Vauchot, Denis Mariano-Goulart
PURPOSE: We investigated whether metabolic, textural and morphological tumoral indices evaluated on baseline PET-CT were predictive of early metabolic response on interim PET-CT in a cohort of patients with bulky Hodgkin and non-Hodgkin malignant lymphomas. METHODS: This retrospective study included 57 patients referred for initial PET-CT examination. In-house dedicated software was used to delineate tumor contours using a fixed 30% threshold of SUV max and then to compute tumoral metabolic parameters (SUV max, mean, peak, standard deviation, skewness and kurtosis, metabolic tumoral volume (MTV), total lesion glycolysis, and area under the curve of the cumulative histogram), textural parameters (Moran's and Geary's indices, energy, entropy, contrast, correlation derived from the gray-level co-occurrence matrix, area under the curve of the power spectral density, auto-correlation distance, and granularity), and shape parameters (surface, asphericity, convexity, surfacic extension, and 2D and 3D fractal dimensions)...
May 17, 2017: Medical Physics
https://www.readbyqxmd.com/read/28498337/imaging-of-early-response-to-predict-prognosis-in-the-first-line-management-of-follicular-non-hodgkin-lymphoma-with-iodine-131-rituximab-radioimmunotherapy
#9
Murali Kesavan, Jan Boucek, William MacDonald, Andrew McQuillan, J Harvey Turner
The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG-PET/CT) three months after induction treatment by Iodine-131-rituximab ((131)I-rituximab). Objective response was determined using the Deauville 5-point scale in 68 prospective clinical trial patients. Baseline (18)F-FDG-PET/CT studies were used to calculate total-metabolic-tumor-volume (TMTV)...
May 12, 2017: Diagnostics
https://www.readbyqxmd.com/read/28485042/prognostic-models-for-primary-mediastinal-thymic-b-cell-lymphoma-derived-from-18-fdg-pet-ct-quantitative-parameters-in-the-international-extranodal-lymphoma-study-group-ielsg-26-study
#10
Luca Ceriani, Maurizio Martelli, Annarita Conconi, Pier L Zinzani, Andrés J M Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria G Cabras, Luigi Rigacci, Luca Giovanella, Emanuele Zucca, Peter W M Johnson
The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value...
May 9, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28483374/-18-f-fdg-pet-ct-in-the-clinical-management-of-patients-with-lymphoma
#11
P Tamayo, A Martín, L Díaz, M Cabrero, R García, P García-Talavera, D Caballero
The aim of this work was to review the current recommendations for staging and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine clinical practice after chemotherapy and/or stem cell transplantation. A five-point scale (5-PS) from the First International Workshop on PET in Lymphoma in Deauville, France, in 2009, was recommended as the standard tool to score imaging to assess treatment response in patients with lymphoma using (18)F-Fluorodeoxyglucose (FDG) PET/CT...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28483373/optimisation-of-metabolic-criteria-in-the-prognostic-assessment-in-patients-with-lymphoma-a-multicentre-study
#12
M Del Puig Cózar-Santiago, J R García-Garzón, M Moragas-Freixa, M Soler-Peter, P Bassa Massanas, M Sánchez-Delgado, R Sanchez-Jurado, J E Aguilar-Barrios, R Sanz-Llorens, J Ferrer-Rebolleda
OBJECTIVE: To compare sensitivity, specificity and predictive value of Deauville score (DS) vs. ΔSUVmax in interim-treatment PET (iPET) and end-treatment PET (ePET), in patients with diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and follicular lymphoma (FL). METHOD: Retrospective longitudinal multicentre study including 138 patients (46 DLBCL, 46 HL, 46 FL), on whom 3 (18)F-FDG PET/CT were performed: baseline, iPET, and ePET. Visual (DS) and semi-quantitative (ΔSUVmax) parameters were determined for iPET and ePET...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28476741/hodgkin-lymphoma-version-1-2017-nccn-clinical-practice-guidelines-in-oncology
#13
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, Richard F Ambinder, Patricia Aoun, Celeste M Bello, Cecil M Benitez, Karl Bernat, Philip J Bierman, Kristie A Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I Gordon, Francisco J Hernandez-Ilizaliturri, Ephraim P Hochberg, Jiayi Huang, Patrick B Johnston, Mark S Kaminski, Vaishalee P Kenkre, Nadia Khan, David G Maloney, Peter M Mauch, Monika Metzger, Joseph O Moore, David Morgan, Craig H Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, Hema Sundar
This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects...
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28411336/fdg-pet-for-therapy-monitoring-in-hodgkin-and-non-hodgkin-lymphomas
#14
REVIEW
Sally F Barrington, Regine Kluge
PET using (18)F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas...
April 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28264597/report-of-the-6th-international-workshop-on-pet-in-lymphoma
#15
Cristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, Caroline Bodet-Milin, Monica Coronado, Barbara Pro, Wong Seog Kim, Judith Trotman, Sally Barrington, Ulrich Duhrsen, Thierry Vander Borght, Elena Zamagni, Françoise Kraeber-Bodéré, Christina Messiou, Alain Rahmouni, Irène Buvat, Marc Andre, Mark Hertzberg, Wim Oyen, Olivier Casasnovas, Stefano Luminari, Laurent Garderet, Françoise Montravers, Carsten Kobe, Regine Kluge, Annibale Versari, Emanuele Zucca, Philippe Moreau, Bruce Cheson, Corinne Haioun, Andrea Gallamini, Michel Meignan
Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented...
March 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#16
RANDOMIZED CONTROLLED TRIAL
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28151888/pediatric-hodgkin-lymphoma-predictive-value-of-interim-18f-fdg-pet-ct-in-therapy-response-assessment
#17
Cristina Ferrari, Artor Niccoli Asabella, Nunzio Merenda, Corinna Altini, Margherita Fanelli, Paola Muggeo, Francesco De Leonardis, Teresa Perillo, Nicola Santoro, Giuseppe Rubini
We investigated the prognostic value of interim F-FDG PET/CT (PET-2) in pediatric Hodgkin lymphoma (pHL), evaluating both visual and semiquantitative analysis.Thirty pHL patients (age ≤16) underwent serial F-FDG PET/CT: at baseline (PET-0), after 2 cycles of chemotherapy (PET-2) and at the end of first-line chemotherapy (PET-T). PET response assessment was carried out visually according to the Deauville Score (DS), as well as semiquantitatively by using the semiquantitative parameters reduction from PET-0 to PET-2 (ΔΣSUVmax0-2, ΔΣSUVmean0-2)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28143954/early-treatment-intensification-with-r-ice-and-90y-ibritumomab-tiuxetan-zevalin-beam-stem-cell-transplantation-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-patients-and-positive-interim-pet-after-4-cycles-of-r-chop-14
#18
MULTICENTER STUDY
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F Seymour, Michael S Hofman, Rodney J Hicks
In the treatment of diffuse large B-cell lymphoma, a persistently positive [(18)F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%...
February 2017: Haematologica
https://www.readbyqxmd.com/read/28132716/-18-f-fdg-pet-mri-in-lymphoma-patients
#19
Eva Ferdová, Jiří Ferda, Jan Baxa
The introduction of hybrid PET/MRI imaging using integrated systems into clinical practice has opened up the possibility of reducing the radiation dose from hybrid imaging by eliminating the contribution from computed tomography. Studies comparing the possibilities of PET/CT and PET/MRI imaging demonstrated it is possible to use the advantages of the high contrast resolution of magnetic resonance for soft tissue and bone marrow along with PET records in a quality comparable to PET/CT imaging. The significant feature for PET imaging in Hodgkińs lymphoma is that it is a tissue with high levels of radiopharmaceutical accumulation, which decreases proportionally after successful therapeutic effect, the effect of therapy is assessed using Deauville score system on interim examinations...
January 23, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28068241/chemotherapy-response-assessment-by-fdg-pet-ct-in-early-stage-classical-hodgkin-lymphoma-moving-beyond-the-five-point-deauville-score
#20
Sarah A Milgrom, Wenli Dong, Mani Akhtari, Grace L Smith, Chelsea C Pinnix, Osama Mawlawi, Eric Rohren, Naveen Garg, Hubert Chuang, Zeinab Abou Yehia, Jay P Reddy, Jillian R Gunther, Joseph D Khoury, Tina Suki, Eleanor M Osborne, Yasuhiro Oki, Michelle Fanale, Bouthaina S Dabaja
PURPOSE: In early-stage classical Hodgkin lymphoma, fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) scans are performed routinely after chemotherapy, and the 5-point Deauville score is used to report the disease response. We hypothesized that other PET-CT parameters, considered in combination with Deauville score, would improve risk stratification. METHODS AND MATERIALS: Patients treated for stage I to II Hodgkin lymphoma from 2003 to 2013, who were aged ≥18 years and had analyzable PET-CT scans performed before and after chemotherapy, were eligible...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
91274
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"